Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy

Hitoshi Kusaba, Hozumi Kumagai, Kyoko Inadomi, Tomoya Matsunobu, Katsumi Harimaya, Kotoe Takayoshi, Shuji Arita, hiroshi ariyama, Koichi Akashi, Eishi Baba

研究成果: ジャーナルへの寄稿記事

抄録

Appropriate antiemetic prophylaxis for moderately emetogenic chemotherapy in patients with non-round cell soft-tissue sarcomas (NRC-STS) remains unclear. We retrospectively investigated efficacy and safety of aprepitant-combined antiemetic prophylaxis in patients with NRC-STS receiving adriamycin plus ifosfamide (AI) therapy. Forty NRC-STS patients were enrolled, their median age was 50 years (range 18-74), and 13 (32.5%) were female. Median cycle number of AI therapy was 4. Twenty patients received the doublet antiemetic prophylaxis (5-hydroxytryptamine-3 receptor antagonist and dexamethasone), and 20 received triplet (5-hydroxytryptamine-3 receptor antagonist, dexamethasone, and aprepitant). In the overall period, complete response rate for nausea and emesis in the triplet group was significantly higher than that in the doublet group (70% vs 35%; P=0.027). Patients with noemesis in the overall period were more frequently observed in the triplet group than in the doublet group (90% vs 65%; P=0.058). All toxicities other than emesis were almost equivalent in both the groups. These results suggest that a triplet antiemetic prophylaxis may be optimal in the treatment with AI therapy for NRC-STS.

元の言語英語
ページ(範囲)e5460
ジャーナルMedicine (United States)
95
発行部数49
DOI
出版物ステータス出版済み - 1 1 2016

Fingerprint

aprepitant
Ifosfamide
Antiemetics
Sarcoma
Doxorubicin
Receptors, Serotonin, 5-HT3
Dexamethasone
Vomiting
Therapeutics
Nausea
Safety
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Medicine(all)

これを引用

Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy. / Kusaba, Hitoshi; Kumagai, Hozumi; Inadomi, Kyoko; Matsunobu, Tomoya; Harimaya, Katsumi; Takayoshi, Kotoe; Arita, Shuji; ariyama, hiroshi; Akashi, Koichi; Baba, Eishi.

:: Medicine (United States), 巻 95, 番号 49, 01.01.2016, p. e5460.

研究成果: ジャーナルへの寄稿記事

@article{c1a6b314eeaa4d9da406f9f87668898f,
title = "Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy",
abstract = "Appropriate antiemetic prophylaxis for moderately emetogenic chemotherapy in patients with non-round cell soft-tissue sarcomas (NRC-STS) remains unclear. We retrospectively investigated efficacy and safety of aprepitant-combined antiemetic prophylaxis in patients with NRC-STS receiving adriamycin plus ifosfamide (AI) therapy. Forty NRC-STS patients were enrolled, their median age was 50 years (range 18-74), and 13 (32.5{\%}) were female. Median cycle number of AI therapy was 4. Twenty patients received the doublet antiemetic prophylaxis (5-hydroxytryptamine-3 receptor antagonist and dexamethasone), and 20 received triplet (5-hydroxytryptamine-3 receptor antagonist, dexamethasone, and aprepitant). In the overall period, complete response rate for nausea and emesis in the triplet group was significantly higher than that in the doublet group (70{\%} vs 35{\%}; P=0.027). Patients with noemesis in the overall period were more frequently observed in the triplet group than in the doublet group (90{\%} vs 65{\%}; P=0.058). All toxicities other than emesis were almost equivalent in both the groups. These results suggest that a triplet antiemetic prophylaxis may be optimal in the treatment with AI therapy for NRC-STS.",
author = "Hitoshi Kusaba and Hozumi Kumagai and Kyoko Inadomi and Tomoya Matsunobu and Katsumi Harimaya and Kotoe Takayoshi and Shuji Arita and hiroshi ariyama and Koichi Akashi and Eishi Baba",
year = "2016",
month = "1",
day = "1",
doi = "10.1097/MD.0000000000005460",
language = "English",
volume = "95",
pages = "e5460",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "49",

}

TY - JOUR

T1 - Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy

AU - Kusaba, Hitoshi

AU - Kumagai, Hozumi

AU - Inadomi, Kyoko

AU - Matsunobu, Tomoya

AU - Harimaya, Katsumi

AU - Takayoshi, Kotoe

AU - Arita, Shuji

AU - ariyama, hiroshi

AU - Akashi, Koichi

AU - Baba, Eishi

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Appropriate antiemetic prophylaxis for moderately emetogenic chemotherapy in patients with non-round cell soft-tissue sarcomas (NRC-STS) remains unclear. We retrospectively investigated efficacy and safety of aprepitant-combined antiemetic prophylaxis in patients with NRC-STS receiving adriamycin plus ifosfamide (AI) therapy. Forty NRC-STS patients were enrolled, their median age was 50 years (range 18-74), and 13 (32.5%) were female. Median cycle number of AI therapy was 4. Twenty patients received the doublet antiemetic prophylaxis (5-hydroxytryptamine-3 receptor antagonist and dexamethasone), and 20 received triplet (5-hydroxytryptamine-3 receptor antagonist, dexamethasone, and aprepitant). In the overall period, complete response rate for nausea and emesis in the triplet group was significantly higher than that in the doublet group (70% vs 35%; P=0.027). Patients with noemesis in the overall period were more frequently observed in the triplet group than in the doublet group (90% vs 65%; P=0.058). All toxicities other than emesis were almost equivalent in both the groups. These results suggest that a triplet antiemetic prophylaxis may be optimal in the treatment with AI therapy for NRC-STS.

AB - Appropriate antiemetic prophylaxis for moderately emetogenic chemotherapy in patients with non-round cell soft-tissue sarcomas (NRC-STS) remains unclear. We retrospectively investigated efficacy and safety of aprepitant-combined antiemetic prophylaxis in patients with NRC-STS receiving adriamycin plus ifosfamide (AI) therapy. Forty NRC-STS patients were enrolled, their median age was 50 years (range 18-74), and 13 (32.5%) were female. Median cycle number of AI therapy was 4. Twenty patients received the doublet antiemetic prophylaxis (5-hydroxytryptamine-3 receptor antagonist and dexamethasone), and 20 received triplet (5-hydroxytryptamine-3 receptor antagonist, dexamethasone, and aprepitant). In the overall period, complete response rate for nausea and emesis in the triplet group was significantly higher than that in the doublet group (70% vs 35%; P=0.027). Patients with noemesis in the overall period were more frequently observed in the triplet group than in the doublet group (90% vs 65%; P=0.058). All toxicities other than emesis were almost equivalent in both the groups. These results suggest that a triplet antiemetic prophylaxis may be optimal in the treatment with AI therapy for NRC-STS.

UR - http://www.scopus.com/inward/record.url?scp=85007505022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007505022&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000005460

DO - 10.1097/MD.0000000000005460

M3 - Article

C2 - 27930525

AN - SCOPUS:85007505022

VL - 95

SP - e5460

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 49

ER -